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Peg-interferon alpha-2a and 2b and ribavirin have
become the mainstays of chronic hepatitis C treat-
ment. Although various cutaneous side effects have
been reported, alopecia areata in its various forms
have rare reports and has not been well categorized.
Here we present a case of alopecia universalis occur-
ring shortly after treatment for chronic hepatitis C, and
we discuss some of the implications this has in under-
standing the pathophysiology of alopecia areata.
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PRESENTATION
A 59-year-old gentleman with a history of patchy alopecia
areata presented with sudden onset alopecia totalis/universalis
within 2 weeks after discontinuing telaprevir, peg-interferon
alfa-2a, and ribavirin therapy for chronic hepatitis C.
HISTORY
He was diagnosed with hepatitis C at the age of 17 years,
but his disease progressed, prompting treatment with triple
therapy. He also had a history of hyperthyroidism possibly
due to Graves’ disease, which had been stable for 15 years
on methimazole, and a history of epilepsy well controlled on
lamotrigine for about 10 years. He had a history of allergic
rhinitis as well. Before starting triple therapy, the thyroid was
destroyed through radioablation.
The patient was treated for a total of 6 months. During the
first 3 months, he was on all three medications, then
peg-interferon-alfa-2a and ribavirin were continued for an
additional 3 months. He reported a slight diffuse increase in
hair shedding throughout therapy but no clear patches. He
was not evaluated by dermatology at that time. Of note, he
was hospitalized for sepsis about 3 months into the treatment.
After completing the therapy, he reported rapid hair loss in
clumps, which ended in near complete loss of hair on the
scalp, eyebrows, eyelashes, and beard. He retains some body
hair. Four months after completing triple therapy, he presented
to dermatology clinic noting no significant hair regrowth.
EXAMINATION
On examination, he had scattered white and gray terminal
hairs on the scalp and complete eyebrow, eyelash, and beard
loss with no evidence of scarring. There were a few patches of
non-scarring alopecia on the upper and lower extremities.
INVESTIGATIONS, MANAGEMENT, AND OUTCOME
Thyroid function tests were within normal limits. Antinuclear
antibody waso1:40. The patient has declined treatment.
DISCUSSION
Interferon-alfa treatment, with and without ribavirin, has been
linked to the exacerbation or onset of several autoimmune
conditions, including thyroid disorders and insulin-dependent
diabetes as well as hair loss, including patchy alopecia
areata, telogen effluvium, and injection site alopecia (Tosti
et al., 1992; Kartal et al., 2007). Telaprevir is a newer protease
inhibitor, which is associated with a severe and charac-
teristic rash but has not been associated with alopecia of
any type. Five cases of alopecia totalis or universalis
during peg-interferon alfa-2a and ribavirin therapy for
chronic hepatitis C have been reported in the literature
CASE REPORT
Table 1. Cases of alopecia universalis (AU) during hepatitis C treatment
Reference Age Sex Medications Time to onset of AU Time to recovery Length of treatment Anti-TPO Abs
Taliani et al., 2005 40 F Peg-IFN2a, RBV 6 months 5 months, with corticosteroids 26 weeks Unknown
36 F Peg-IFN2b, RBV 9 months 6 months, spontaneous 48 weeks No
Demirturk et al., 2006 57 M Peg-IFN2a, RBV 6–9 months 9 months to 1 year 48 weeks Yes
Kartal et al., 2007 34 F Peg-IFN2a, RBV 4 months 3–8 monthsþ 48 weeks Yes
Shafa et al., 2010 71 F Peg-IFN2a, RBV 3 months Never 3 months Unknown
Abbreviations: F, female; IFN, interferon; M, male; RBV, ribavirin; TPO Ab, thyroid peroxidase antibody.
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(Taliani et al., 2005, Demirturk et al., 2006; Kartal et al., 2007;
Shafa et al., 2010) (Table 1). All cases except one showed
complete regrowth within about 1 year of discontinuing
therapy. One patient had been treated with interferon-alfa
monotherapy in the past with associated alopecia of unknown
type (Shafa et al., 2010).
This case stands out as the first reported case with a
previous history of alopecia areata unrelated to interferon,
and the first to have onset after therapy was disconti-
nued. These cases represent a striking adverse event with
significant clinical implications for patients undergoing treat-
ment for chronic hepatitis C. The immunological implications
regarding the role of interferon alpha in triggering alopecia
areata onset, recurrence, and/or progression outside the con-
text of hepatitis C is also of great interest and could elucidate
some of the mechanisms behind this common disease.
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